Spravato (Esketamine) 56mg Nasal Spray Dose Kit: FDA-Approved Data for Treatment-Resistant Depression - Dataset - NIASRA
This dataset provides a comprehensive technical and clinical overview of Spravato (Esketamine) 56mg Nasal Spray, the first FDA-approved nasal treatment for treatment-resistant depression (TRD). Each d...
- By Lyfeunit Ketamine for TRD,
- Published on
1look4.com is a place where you can share your Story/ Product/ Review/ Profile URL and get noticed by the world.
Your ads here